Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 40.0% in October

Ainos, Inc. (NASDAQ:AIMDGet Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 143,300 shares, a drop of 40.0% from the October 15th total of 238,800 shares. Approximately 5.7% of the shares of the company are short sold. Based on an average daily volume of 656,000 shares, the days-to-cover ratio is presently 0.2 days.

Ainos Stock Down 1.2 %

AIMD opened at $0.49 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.33. Ainos has a 12-month low of $0.40 and a 12-month high of $4.29. The firm has a 50 day moving average of $0.51 and a two-hundred day moving average of $0.71.

Ainos (NASDAQ:AIMDGet Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter. Ainos had a negative return on equity of 75.16% and a negative net margin of 15,348.14%.

About Ainos

(Get Free Report)

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.

Further Reading

Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.